Updates from the Teplizumab Trial: You’re Not Going to Believe the Results
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for…
ADA’s Scientific Sessions: Day 2
The American Diabetes Association’s Scientific Sessions is here! Until June 16, scientists will present some of the most updated topics,…
ADA’s Scientific Sessions: Day 1
The American Diabetes Association’s Scientific Sessions is here! Until June 16, scientists will present some of the most updated topics,…
Breakthrough T1D Top Advances Over the Past Year
At Breakthrough T1D, we are committed to funding the development of new therapies to keep people with type 1 diabetes…
Breakthrough T1D Heads, Virtually, to ADA’s 80th Scientific Sessions
The American Diabetes Association’s (ADA) 80th Scientific Sessions is almost here! From June 12-16, scientists and healthcare professionals will gather,…
The Breakthrough T1D Journey: Where It All Began
Fifty years ago, two mothers came together to make the world a better place for their children and for other…
JDRF-Beyond Type 1 Alliance Announce Global Covid-19 Prevention Guidance Campaign
The Breakthrough T1D-Beyond Type 1 Alliance has brought together leaders of the international diabetes community to create recommendations to curb…
Meet the Scientist: Developing Devices That Resist Autoimmune Attacks
What might be the next best thing to having a healthy pancreas that is steadily producing insulin? It could be…
Insulet to Supply 6 months of Product to Customers in Dire Need
Omnipod® producer Insulet announced today that it would expand its financial assistance program to those U.S. customers who had lost…
Novo Nordisk Offers 90 Days of Free Insulin to Those Left Uninsured Because of the Coronavirus
Today, leading insulin manufacturer Novo Nordisk announced that it would offer 90 days of free insulin to those who lost…
